Investigations with 1,4-bis-(2'-mesyloxyethylamino)-1,4-dideoxy-meso-erythritol (R-74).
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D004896:Erythritol / Q000031:analogs & derivatives; D005021:Ethylamines / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D013451:Sulfonic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D013780:Tetroses / Q000008:administration & dosage / Q000627:therapeutic use*; D014565:Urogenital Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D005021:Ethylamines; D013451:Sulfonic Acids; D013780:Tetroses; D004896:Erythritol; C000288:ritrosulfan